RET and medullary thyroid gland carcinoma: As such, vandetanib (brand name, Caprelsa) and cabozantinib (brand name, Cabometyx), which inhibit RET and other tyrosine kinase receptors, and more advanced RET inhibitors, praseltinib (brand name, Gavreto) and selpercatinib (brand name, Retevmo), are now available to treat patients with advanced MTC [6,7,8,9].